Endothelium-targeted pharmacotherapeutics for the treatment of stroke [0.03%]
针对血管内皮细胞的药物治疗在卒中治疗中的应用
Gary Danton,Brant D Watson,Ricardo Prado et al.
Gary Danton et al.
The pathophysiology of stroke in humans is much more complex than what is typically studied in animal models. Embolic stroke models are more complex than pure ischemia models, but are more representative of human disease and may be particul...
Daniela Salvemini,Salvatore Cuzzocrea
Daniela Salvemini
Oxidative stress results from an oxidant/antioxidant imbalance: an excess of oxidants relative to the antioxidant capacity. Recent evidence strongly suggests that oxidant stress plays a major role in several aspects of ischemia and reperfus...
Shaker A Mousa,Omar Iqbal,Jawed Fareed
Shaker A Mousa
Although angioplasty, stenting and thrombolysis of the cerebral circulation are being attempted with increasing frequency, antithrombotic and antiplatelet regimens have not yet been standardized in the treatment of stroke. Safety and effica...
Pexelizumab Alexion [0.03%]
巴利昔单抗(Alexion)
Per A Whiss
Per A Whiss
Alexion and Procter & Gamble (P&G) are developing pexelizumab (h5G1.1-SC), a short-acting, recombinant complement C5 inhibitor for the potential treatment of complications of cardiovascular surgery, such as complement activation during card...
BX-471 Berlex [0.03%]
伯莱沙BX-471
Mariano J Elices
Mariano J Elices
Berlex and its parent company, Schering AG, are developing BX-471 (also known as ZK-811752), the lead in a series of non-peptide chemokine receptor 1 (CCR1) antagonists, for the potential treatment of autoimmune diseases, in particular mult...
Cannabinoids in the treatment of pain and spasticity in multiple sclerosis [0.03%]
大麻酚用于治疗多发性硬化症疼痛及肌张力障碍症状
Paul F Smith
Paul F Smith
There is a large amount of evidence to support the view that the psychoactive ingredient in cannabis, delta9-tetrahydrocannabinol (delta9-THC), and cannabinoids in general, can reduce muscle spasticity and pain under some circumstances. Can...
ATP-binding cassette transporters in macrophages: promising drug targets for treatment of cardiovascular disease [0.03%]
巨噬细胞中的ATP结合盒转运蛋白：心血管疾病治疗的潜在药物作用靶点
Gerd Schmitz,Wolfgang Drobnik
Gerd Schmitz
Numerous ATP-binding cassette (ABC) transporters are expressed in monocyte-derived macrophages and are subject to sterol-dependent regulation. ABCA1 has been identified as a key regulator of macrophage cholesterol efflux and HDL-mediated re...
AZD-2563 AstraZeneca [0.03%]
AZD-2563 阿斯利康
Alan P Johnson
Alan P Johnson
AstraZeneca is developing AZD-2563, an oxazolidinone with a novel mechanism of action, for the potential treatment of gram-positive bacterial infections, including those caused by multidrug-resistant strains [349551], [399542]. As of Decemb...
MitoExtra SuperGen [0.03%]
线粒体超级基因型数据分析平台
Konstantina Grosios
Konstantina Grosios
SuperGen Inc is developing a cyclodextrin-based reformulation of mitomycin C (MitoExtra) for the potential treatment of gastic, pancreatic, breast lung and colorectal cancers. In April 2002, the NDA was pending approval from the US FDA afte...
Chemosensitization of solid tumor cells by alteration of their susceptibility to apoptosis [0.03%]
通过改变细胞对凋亡的敏感性使实体瘤细胞增敏
Ian A Cree,Louise Knight,Federica Di Nicolantonio et al.
Ian A Cree et al.
Chemosensitization strategies use the administration of one drug or agent to render cancer cells more susceptible to a second agent. Usually this involves enhanced drug metabolism, improvement of drug uptake or blockage of resistance mechan...